Efinaconazole, is the Gx v Jublia and subject to the patent...

Efinaconazole, is the Gx v Jublia and subject to the patent litigation with Bausch, whilst ACR has settled its position legally there were at least 10 other parties that need to do the same. FDA approval would have conditional subject to the conclusion of all litigation, can only assume that this is still going on.

Lidocaine, interesting to me. I went back and looked at the July 21 approval announcement, annual sales USD21mil (which is not a lot) based on Sep20 data with no information provided around competitive environment, . I just wonder if within the 12-18mths post Sep20, enduring delays caused by the Harris bankruptcy, 2/3 or 4 competitors haven't entered the market and our product has become uncommercial to launch, ie, cost to manufacture (high because low volumes) > selling price.

All just my thoughts but would appreciate some comms from company.